{"id":39122,"date":"2023-07-22T12:23:33","date_gmt":"2023-07-22T16:23:33","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/gilead-ends-late-stage-trial-of-blood-cancer-treatment\/"},"modified":"2023-07-22T12:23:35","modified_gmt":"2023-07-22T16:23:35","slug":"gilead-ends-late-stage-trial-of-blood-cancer-treatment","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=39122","title":{"rendered":"Gilead ends late-stage trial of blood cancer treatment"},"content":{"rendered":"<div id=\"js-article__body\" itemprop=\"articleBody\" data-sbid=\"WP-MKTW-0002309367\" role=\"document\">\n<p>Shares of Gilead Sciences Inc.<br \/>\n        GILD,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/210293917\/composite\" class=\"positive\">+0.88%<\/bg-quote><br \/>\n       dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment for a rare type of blood cancer after an analysis. \u201cThe health and well-being of patients are our top priorities and while this is disappointing news it confirms the challenges of treating [higher-risk myelodysplastic syndromes,] where no new class of treatments have been approved in nearly 20 years,\u201d Gilead\u2019s Chief Medical Officer Merdad Parsey said in a statement. One of the treatments involved, magrolimab, is a potential immunotherapy with a clinical development program spanning ten potential indications for cancers, including ongoing trials in solid tumors and two trials in certain types of leukemia, Gilead said. Shares of Gilead ended the regular trading day up 0.9%.  <\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.marketwatch.com\/story\/gilead-ends-late-stage-trial-of-blood-cancer-treatment-e1324b2f?mod=investing\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment for a rare type of blood cancer after an analysis. \u201cThe health and well-being of patients are our top priorities and while this is disappointing news [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-39122","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead ends late-stage trial of blood cancer treatment | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=39122\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead ends late-stage trial of blood cancer treatment | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=39122\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-22T16:23:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-22T16:23:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/MW-GP644_MicroS_ZG_20180906154215.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1320\" \/>\n\t<meta property=\"og:image:height\" content=\"742\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=39122#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=39122\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Gilead ends late-stage trial of blood cancer treatment\",\"datePublished\":\"2023-07-22T16:23:33+00:00\",\"dateModified\":\"2023-07-22T16:23:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=39122\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=39122#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=39122\",\"url\":\"https:\/\/ifintechworld.com\/?p=39122\",\"name\":\"Gilead ends late-stage trial of blood cancer treatment | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-07-22T16:23:33+00:00\",\"dateModified\":\"2023-07-22T16:23:35+00:00\",\"description\":\"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=39122#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=39122\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=39122#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead ends late-stage trial of blood cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead ends late-stage trial of blood cancer treatment | iFintechWorld","description":"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=39122","og_locale":"en_US","og_type":"article","og_title":"Gilead ends late-stage trial of blood cancer treatment | iFintechWorld","og_description":"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial","og_url":"https:\/\/ifintechworld.com\/?p=39122","og_site_name":"iFintechWorld","article_published_time":"2023-07-22T16:23:33+00:00","article_modified_time":"2023-07-22T16:23:35+00:00","og_image":[{"width":1320,"height":742,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/MW-GP644_MicroS_ZG_20180906154215.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=39122#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=39122"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Gilead ends late-stage trial of blood cancer treatment","datePublished":"2023-07-22T16:23:33+00:00","dateModified":"2023-07-22T16:23:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=39122"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=39122#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=39122","url":"https:\/\/ifintechworld.com\/?p=39122","name":"Gilead ends late-stage trial of blood cancer treatment | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-07-22T16:23:33+00:00","dateModified":"2023-07-22T16:23:35+00:00","description":"Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=39122#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=39122"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=39122#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Gilead ends late-stage trial of blood cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/39122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39122"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/39122\/revisions"}],"predecessor-version":[{"id":39123,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/39122\/revisions\/39123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1383"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}